Karimah Es Sabar Overview

  • Primary Position
  • Board Member

  • Primary Industry
  • Healthcare

  • Active Board Seats
  • 6

  • Med. Deal Size

  • Med. Valuation

Karimah Es Sabar General Information

Biography

Ms. Karimah Es Sabar serves as Board Member at PHEMI Systems. Ms. Es Sabar also served as Chief Executive Officer & General Partner at Quark Venture. She serves as a Board Member at GlycoNet, ARTMS Products, and Canary Medical. A highly-recognized Canadian life sciences leader with broad global experience, she has had a successful career spanning multi-national pharmaceutical/biotechnology companies, start-up companies, not-for-profit organizations, and venture investment firms. She has provided leadership in marketing, business development, strategic alliances, global collaborations, public-private partnerships, developing and executing innovation and translation strategies in the life science sector, and biotech investment. In July 2016, she accepted the position of CEO & Partner at Quark Venture Inc., a venture investment firm focused on life sciences investment, to expand and lead their health sciences enterprise. In partnership with leading Chinese private and public investment banks, one of the largest global health sciences venture funds will be headquartered in Vancouver, Canada with offices in Boston, Hong Kong, and Chengdu, to invest in North American and international companies. The fund is diversified to invest in disruptive pre-clinical and clinical-stage companies, IPOs, and publicly traded companies in the areas of drug development, vaccines, diagnostics, medical devices, health IT, and novel emerging convergent technologies. In 2009, she joined The Centre for Drug Research and Development, Canada's national drug development and commercialization center, as Senior Vice-President of Business and Strategic Affairs, leading its business functions and successfully building an array of national and international alliances and strategic industry partnerships. In 2012, she took on the role of President and CEO responsible for developing and executing the overall strategic direction of the organization. Since she joined CDRD, she enabled new public and private sector funding of over $180M, multiple commercial transactions including 6 spin-out companies and an M&A, and grew the organization with expanded national and international reach to include partnerships right across Canada and in 12 countries on five continents - firmly establishing its reputation as one of the world's leading pre-clinical translational research and commercialization centers. In this vein, she was also appointed Founding Chair of the Global Alliance of Leading Drug Discovery and Development Centres in 2013, an association of international peer organizations dedicated to translating health research into new medicines, the formation of which she spearheaded. She took on the role of leading BC Biotech in 2005, re-engineering and rebranding the organization to LifeSciences BC. As President, she led the organization to its greatest levels of success as a strong business development organization for the life science industry and the scientific research community. She holds a BS degree in Biochemistry & Chemistry from the University of Salford & also completed an MS degree in Neurochemistry from the University of London. He served as Board Member at Sitka Biopharma.

Contact Information

Primary Position
Board Member, PHEMI Systems
Education
University of London, MS (Master of Science)
University of Salford, BS (Bachelor of Science)
Gender
Female
Phone
+1 (604)
Address
  • 777 Hornby Street
  • Suite 600
  • Vancouver, British Columbia V6Z 1S4
  • Canada
+1 (604)

Karimah Es Sabar Positions (1)

Firm name Firm type Title Location Industry Since
Global Pharmaceutical Commercialization Center Company Chief Executive Officer Chengdu, China Pharmaceuticals

Karimah Es Sabar Board Seats (6)

Company Industry Ownership Status Financing Status Location Since
ARTMS Other Devices and Supplies Acquired/Merged (Operating Subsidiary) Formerly VC-backed Burnaby, Canada
Canary Medical Medical Records Systems Privately Held (backing) Venture Capital-Backed Carlsbad, CA
Capricor Therapeutics Biotechnology Publicly Held Formerly VC-backed San Diego, CA
GlycoNet Edmonton, Canada
PHEMI Systems Database Software Privately Held (backing) Venture Capital-Backed Vancouver, Canada

Karimah Es Sabar Lead Partner on Deals (13)

Karimah Es Sabar has been the lead partner on 13 deals. Their latest deal was with EyeYon Medical, a therapeutic devices company. The deal was made for on 15-Mar-2021.

Company Deal Date Deal Type Deal Size Deal Status Industry Location
EyeYon Medical 15-Mar-2021 Later Stage VC (Series C) Completed Therapeutic Devices Ness Ziona, Israel
CalciMedica 11-Mar-2021 Completed Drug Discovery San Diego, CA
V-Wave 22-Sep-2020 Completed Therapeutic Devices Caesarea, Israel
ARTMS 20-May-2020 Completed Other Devices and Supplies Burnaby, Canada
EnClear Therapies 18-Feb-2020 Completed Therapeutic Devices Newburyport, MA
Sitka Biopharma 11-Feb-2019 Completed Drug Delivery Vancouver, Canada
Canary Medical 01-Jan-2019 Completed Medical Records Systems Carlsbad, CA
SQZ Biotech 14-Aug-2018 Completed Drug Delivery Watertown, MA
Lyndra (China) Pharmaceuticals Company 01-May-2018 Joint Venture Completed Pharmaceuticals Chengdu, China
Eloxx Pharmaceuticals 02-Aug-2017 Later Stage VC (Series C) Completed Biotechnology Watertown, MA

Karimah Es Sabar Network (167)

Board Members (44)

Name Company Representing Location From
Mike Satterfield PHEMI Systems Yaletown Partners Vancouver, Canada
Khaled Emam Ph.D Canary Medical Self Carlsbad, CA
PHEMI Systems Self Vancouver, Canada
GlycoNet Self Edmonton, Canada
ARTMS Self Burnaby, Canada

Portfolio Executives (119)

Name Company Role Deal date Location
Arie Marcovich MD EyeYon Medical Co-Founder 15-Mar-2021 Ness Ziona, Israel
Dmitry Dubson EyeYon Medical Chief Technology Officer & Vice President, Research & Development 15-Mar-2021 Ness Ziona, Israel
EyeYon Medical Co-Founder & Chief Executive Officer 15-Mar-2021 Ness Ziona, Israel
EyeYon Medical Co-Founder & Medical Director 15-Mar-2021 Ness Ziona, Israel
EyeYon Medical Head of Sales & Marketing 15-Mar-2021 Ness Ziona, Israel

Fund Team Members (4)

Name Investor Fund Fund Location
Zafrira Avnur Ph.D GF Securities Global Health Sciences Fund Guangzhou, China
Zafrira Avnur Ph.D Quark Venture Global Health Sciences Fund Vancouver, Canada
GF Securities Guangzhou, China
Quark Venture Vancouver, Canada
GF Securities Guangzhou, China

Karimah Es Sabar Affiliated Funds (1)

Fund Investor Fund Type Status Vintage Size Dry Powder IRR IRR Quartile
Global Health Sciences Fund GF Securities Venture - General Closed 2016

Karimah Es Sabar FAQs

  • Who is Karimah Es Sabar?

    Ms. Karimah Es Sabar serves as Board Member at PHEMI Systems.

  • How much does Karimah Es Sabar typically invest?

    Karimah Es Sabar's median deal size is .

  • What is Karimah Es Sabar’s main position?

    Karimah Es Sabar’s primary position is Board Member.

  • How many active board seats does Karimah Es Sabar hold?

    Karimah Es Sabar holds 6 board seats including ARTMS, Canary Medical, Capricor Therapeutics, GlycoNet, and PHEMI Systems.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »